This year, there are two open seats on the Radiosurgery Society® (RSS) Board of Directors (BOD). Professional Members of the RSS are hereby notified that three candidates have been nominated to run for the following open seats:
The BOD At-Large seat is a three-year term, beginning April 1, 2025, through March 31, 2028. Eligible RSS Members will choose two (2) BOD At-Large candidates.
All Professional Members of the RSS who are in good standing* as of March 7, 2025, will be eligible to vote. Online voting, via electronic ballot, will commence on March 10, 2025, and will close at 5:00 pm Pacific Time on March 24, 2025.
On March 10, 2025, electronic ballots will be emailed to all eligible RSS Members. If you do not receive your ballot, please contact us.
To verify your eligibility:
Dr. Banu Atalar is a professor of Radiation Oncology at Acibadem Mehmet Ali Aydinlar University in Istanbul, Turkiye, specializing in stereotactic radiosurgery (SRS) with a clinical focus on CNS, Lung, and Gastrointestinal malignancies. She completed her medical degree and Radiation Oncology residency in Istanbul University, Turkiye. Dr. Atalar completed a Clinical Research Fellowship in SRS at Stanford University in 2011 and since than dedicated her career to advancing precision radiotherapy techniques such as Stereotactic Radiosurgery and MR-guided Adaptive Stereotactic Radiosurgery. With over 70 peer-reviewed publications, she actively contributes to the evolution of SRS techniques and their integration into clinical practice. Dr. Atalar's research and organizational efforts have been instrumental in advancing cancer care and education, evident in her extensive publications and successful organization of international events.
She has been an active member of the Radiosurgery Society (RSS) since 2012 and serves on the RSS Scientific Meeting Organization Committee, contributing to the development of global SRS education and collaboration. Throughout her career, Dr. Atalar has actively engaged with international organizations like ESTRO, ASTRO, and ASCO (served on the ASCO Resource Stratified Guidelines Committee).
Currently she serves as the Chair of the National Societies Committee for ESTRO (2024-2027), and plays a pivotal role in fostering international partnerships and strengthening the role of national societies in the global oncology landscape. She is also the “President of the Turkish Society for Radiation Oncology (TROD)”, working to advance educational programs and interdisciplinary cooperation in radiation oncology.
Jonathan Haas is the Chairman of the Department of Radiation Oncology at Perlmutter Cancer Center at NYU Long Island Radiation Oncology and Clinical Professor of Radiation Oncology at NYU Grossman Long Island School of Medicine. He is a Founding Lifetime Member of the RSS and was an active member of the CyberKnife Society prior to that involved in the discussions to form the RSS out of the CKS as a platform neutral society. Dr. Haas has been named a Castle Connolly New York Metropolitan Top Doctor, New York Magazine Top Doctor, and New York Newsday Top Doctor. He is a regular contributing guest on WABC and WOR radio in New York, Sirius Doctor Radio, and was the first Radiation Oncologist to complete Cyberknife training in the New York metropolitan area in 2005. He has published extensively on the use of CyberKnife for Prostate, Breast, Lung, Spine/CNS, and Gynecologic malignancies. He currently serves as the Genitourinary Site Leader for The Radiosurgery Society and is on the RSS Scientific Committee. He has taught physicians in this country and abroad on clinical utilization of SBRT. He directs an international annual course on SBRT for Prostate Cancer. His Department at NYU Long Island is the largest CyberKnife Department in the United States and largest CyberKnife Prostate Department in the world. He was instrumental in negotiations with insurance companies in the early 2000’s to have SBRT for prostate cancer covered by US insurance companies. His primary research interests are the use of SBRT for prostate and breast cancer and is currently a Principal Investigator on an IRB approved study for 2 fraction Prostate SBRT with SIB tailored by genomics. In addition he is also an investigator in looking at strategies to omit ADT in subsets of patients with unfavorable intermediate risk disease receiving Prostate SBRT.
Dr. Simon Lo is Professor of Radiation Oncology and Neurological Surgery at the University of Washington (UW). He is also Director of SBRT at UW. Dr. Lo has edited 5 comprehensive textbooks in SRS/ SBRT in addition to 4 other comprehensive textbooks and has published close to 300 full peer-reviewed papers with a majority of which on SRS/ SBRT for all body sites, including publications in Lancet Oncology, JAMA Oncology, Science Translational Medicine, Journal of Clinical Oncology, and Neuro Oncology. He has built or led the SBRT programs in 3 NCI-designated Comprehensive Cancer Centers. He is a member of the Board of Directors and the Medical Director of the Distinction in Practice of Stereotactic Radiotherapy Accreditation Program for Radiosurgery Society. He is also Steering Committee Member for International Stereotactic Radiosurgery Society Guidelines for Extracranial Sites. Dr. Lo has led or participated in numerous guidelines in CNS tumors, spinal metastasis, bone metastasis, renal cell carcinoma, SRS, and SBRT. He is a Fellow of ACR and ASTRO. In 2019, he was granted the Lifetime Achievement Award by the Society for Palliative Radiation Oncology. He is the Past President of the Radiation Oncology Chapter of American College of Radiology. He is also a cofounder of the International Radiosurgery Consortium of the Kidney (IROCK). He is the Scientific Program Chair of American Radium Society (2024-2025). Dr. Lo has won national teaching awards (ARRO) and is a member of the American Board of Radiology Oral Examination Committee in Central Nervous System and Pediatric Tumors.
* Members In Good Standing
Per the Bylaws, Section 2.05, Members in Good Standing are Professional Members (those who are in the following categories: Professional Physician, Professional Non-Physician, Professional Resident/Trainee) who have paid the required dues, fee, and assessments if any, and who are not suspended.